Active Ingredient History

NOW
  • Now
Filibuvir was a non-nucleoside orally available NS5B inhibitor developed by Pfizer for the treatment of hepatitis C. It binds to the non-catalytic Thumb II allosteric pocket of NS5B viral polymerase and causes a decrease in viral RNA synthesis. It is a potent and selective inhibitor, with a mean IC50 of 0.019 μM against genotype 1 polymerases. Several filibuvir-resistant mutations have been identified, M423 being the most common that occurred after filibuvir monotherapy. It was intended to be taken twice-daily.   Wikipedia

  • SMILES: CCc1cc(CC[C@@]2(CC(=C(Cc3nc4nc(C)cc(C)n4n3)C(=O)O2)O)C5CCCC5)cc(CC)n1
  • InChIKey: SLVAPEZTBDBAPI-GDLZYMKVSA-N
  • Mol. Mass: 503.65
  • ALogP: 5.12
  • ChEMBL Molecule:
More Chemistry
6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-(1,2,4)triazolo(1,5-a)pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-one | filibuvir | pf00868554 | pf 00868554 | pf-00868554 | pf868554 | pf 868554 | pf-868554

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue